AbbVie's Etentamig Meets Both Primary Endpoints in Phase 3 CERVINO Trial for Triple-Class Exposed Myeloma

AbbVie (NYSE: ABBV) reported positive topline results from the Phase 3 CERVINO trial of etentamig (ABBV-383), an investigational BCMA x CD3 bispecific T-cell engager, versus investigator’s choice of standard available therapies (SAT) in triple-class exposed relapsed/refractory multiple myeloma (RRMM). The study met both dual primary endpoints of objective response rate (ORR) and progression-free survival (PFS), and the independent data monitoring committee recommended unblinding the study.

The numbers

At the first planned efficacy interim analysis, CERVINO enrolled 393 patients who had received a median of three prior lines of therapy, with a median follow-up of 11.4 months:

• ORR: 74.0% for etentamig vs. 45.7% for SAT (P<0.0001)
• PFS: hazard ratio 0.40 (95% CI 0.29-0.54; P<0.0001), a 60% reduction in the risk of progression or death, consistent across all prespecified subgroups
• 12-month overall survival: 87.9% vs. 72.0% (HR 0.48; nominal P=0.0012) - but the prespecified efficacy boundary for OS was not crossed at this cutoff

The safety story

The profile AbbVie is leading with is safety and convenience. Etentamig uses a single step-up dose followed by monthly (Q4W) dosing from initiation. Cytokine release syndrome occurred in 28.3% of patients but was predominantly grade 1 (23.9%), with no grade 3 or higher events. Immune effector cell-associated neurotoxicity syndrome (ICANS) was reported in one patient (0.9%, grade 1). Grade 5 (fatal) infections were 1.5% for etentamig versus 3.1% for SAT, though grade 3/4 infections ran higher for etentamig (27.7% vs. 19.2%), and discontinuations related to treatment-emergent adverse events were 3.6% versus 9.6%.

Why it matters

Etentamig is a second-generation BCMA bispecific built around a low-affinity CD3 binding domain (designed to cut CRS and infections), a high-avidity bivalent BCMA-binding domain, and retained FcRn binding that enables monthly dosing. That combination targets the adoption bottlenecks that have held back first-generation bispecifics like J&J’s TECVAYLI and TALVEY - namely step-up dosing schedules and the specialized monitoring infrastructure that limits access outside academic centers.

The efficacy is strong but not a clean win: OS favored etentamig numerically but did not cross its prespecified significance boundary, so the case for the drug rests on the safety and convenience profile rather than a demonstrated survival benefit. AbbVie said it plans to discuss the results with global regulators to determine next steps; full data, including depth of response and measurable residual disease negativity, land in a plenary session at the International Myeloma Society annual meeting on September 25.

For context on the crowded field etentamig is entering, see our earlier coverage of J&J’s TECVAYLI plus TALVEY combo, which cut progression risk by 89% in its own Phase 3 trial, and our breakdown of CAR-T versus bispecifics in multiple myeloma.

ABBV shares were little changed Thursday, last around $260 against a prior close of $261.72, reflecting a readout that is material to AbbVie’s oncology pipeline but small relative to its market capitalization.

What It Means for the Trade

The flat stock reaction is correct for a mega-cap, but the readout deserves more weight than the tape gave it, because it clarifies the myeloma competitive map for the next two years. The headline is the PFS hazard ratio: 0.40 (95% CI 0.29-0.54) against investigator’s choice of therapy in triple-class exposed RRMM, with a 60% reduction in progression or death risk, consistent across prespecified subgroups. That is a strong number in a population with a median of three prior lines. The ORR delta — 74.0% versus 45.7% — is the number that matters for accelerated approval mechanics, and the dual primary endpoint design means AbbVie can go to regulators with both.

What the trial did not deliver is equally important to price correctly: the 12-month OS favored etentamig (87.9% vs. 72.0%, HR 0.48) but did not cross its prespecified boundary. That is a numerically strong but statistically unconfirmed survival signal. In myeloma, where bispecifics and CAR-T compete on sequencing and durability, an unconfirmed OS trend is a placeholder — it can mature into a confirmed benefit at final analysis, or it can decay as crossover and subsequent therapies muddy the tail. Underwrite the drug on PFS, ORR, and the safety/convenience profile; treat the OS trend as free optionality, not as a marketed claim.

Mechanism and Competitive Context

Etentamig’s design choices are aimed squarely at the adoption bottlenecks that have kept first-generation BCMA bispecifics from expanding beyond academic centers. The low-affinity CD3 arm is engineered to reduce CRS — and the 28.3% CRS rate, almost entirely grade 1, with no grade 3 or higher, is a materially cleaner profile than the class’s early experience. The retained FcRn binding enabling true monthly Q4W dosing after a single step-up dose attacks the operational burden: first-generation bispecifics often require intensive step-up schedules and repeated monitoring visits that community oncology infrastructure struggles to support. If the safety profile holds at scale, etentamig’s addressable setting expands from the academic relapse centers where bispecifics currently live into the community clinics where most myeloma patients are actually treated.

The competitive context frames the stakes. J&J’s TECVAYLI plus TALVEY combination posted an 89% risk reduction in its own Phase 3 (cross-trial, not head-to-head — different designs, different control arms), which sets a high bar on efficacy, but that regimen means two bispecifics and a demanding administration schedule. CAR-T holds the deepest responses in the class but is capacity-constrained with long turnaround times. The triple-class exposed population is growing every year as earlier lines adopt BCMA-directed therapy, and the winners will be the assets that combine class-level efficacy with the least operational friction. Etentamig’s bet is that “nearly as effective, far easier to give” wins share in the real world.

Risks and What Could Go Wrong

1. The infection signal cuts the wrong way: grade 5 infections were lower for etentamig (1.5% vs. 3.1%) but grade 3/4 infections ran higher (27.7% vs. 19.2%). Chronic T-cell redirection comes with immunosuppression; if that gradient persists at scale, the convenience story gets harder to sell.
2. The unconfirmed OS trend decays at final analysis, handing competitors a label-based superiority argument in a market that moves on survival claims.
3. Regulators push back on the single-agent filing strategy or request additional data; AbbVie said it will “discuss next steps” with regulators, which leaves filing timing open.
4. Competitive crowding: J&J’s bispecific franchise, CAR-T capacity growth, and any front-line expansion of existing BCMA assets all compress the window in which etentamig can establish itself in the triple-class exposed niche.

The position read: for ABBV, this is a pipeline-validation event, not a stock mover — size it as one chapter in the post-Humira oncology rebuild, and mark the September 25 IMS plenary as the next checkpoint where depth-of-response data either strengthens or complicates the story.